Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

Go back to Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
(NASDAQ: PPCB) Delayed: 0.28 +0.01 (3.70%)
Previous Close $0.27    52 Week High $ 
Open $0.28    52 Week Low $ 
Day High $0.28    P/E N/A 
Day Low $0.25    EPS $ 
Volume 257,031       

(NASDAQ: PPCB) Delayed: 0.28 +0.01 (3.70%)
Previous Close $0.27    52 Week High $ 
Open $0.28    52 Week Low $ 
Day High $0.28    P/E N/A 
Day Low $0.25    EPS $ 
Volume 257,031